USA flag logo/image

An Official Website of the United States Government

Diagnostic Assays for Rheumatic Diseases

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
54263
Program Year/Program:
2001 / STTR
Agency Tracking Number:
1R41AI050350-01
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
JK AUTOIMMUNITY, INC.
755 Research ParkWay OKLAHOMA CITY, OK 73104
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2001
Title: Diagnostic Assays for Rheumatic Diseases
Agency: HHS
Contract: PHS2001-2
Award Amount: $99,999.00
 

Abstract:

DESCRIPTION (provided by applicant): The diagnosis of systemic lupus erythematosus is a serious public health problem. Almost 90 percent of the 2,000,000 people who have been told that they have lupus do not fulfill the diagnostic criteria to classify a person as having lupus. The laboratory test used to screen for lupus is largely to blame. This antinuclear antibody test and its derivatives are very sensitive (>95 percent), but are not specific (<2 percent). Other serological tests for lupus are specific, but not sensitive (i.e., anti-native DNA and anti-Sm autoantibodies). Through fine specificity immunochemical work, peptides have been found that tend to be bound by normal sera and others that are bound by lupus sera. Our first goal is to develop these assays for commercial application. Less expensive antigen-antibody binding reagents and conditions suitable for commercial performance are sought. Four substrate chemistries will be explored. Other goals include developing peptide-based assays to replace existing assays for anti-Sm, anti-nRNP, and anti-Ro. Some preliminary data suggest that patients with lupus nephritis who do not respond to aggressive immunosuppressive therapy can be identified through a peptide-based solid phase assay. The development of this assay will also be explored. The successful completion of this project will lead to improved clinical care of patients with suspected systemic lupus erythematosus by helping make products available to the marketplace that will more precisely diagnose this disease and assist its management. PROPOSED COMMERCIAL APPLICATION: The products will be used to help diagnose systemic lupus erythematosus, to identify particular antibody systems with prognostic value, and to identify patients who are not likely to respond to immunosuppressive therapy.

Principal Investigator:

John B. Harley
4052717768
JOHN-HARLEY@OMRF.OUHSC.EDU

Business Contact:

Kaufman, kenneth
4052717406
KAUFMANK@OMRF.OUHSC.EDU
Small Business Information at Submission:

JK AUTOIMMUNITY, INC.
800 RESEARCH PKW, STE 100 OKLAHOMA CITY, OK 73104 OKLAHOMA CITY, OK 73104

EIN/Tax ID: 731565223
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
Research Institution Information:
OKLAHOMA MEDICAL RESEARCH FOUNDATION
OKLAHOMA MEDICAL RESEARCH FOUNDATION
OKLAHOMA CITY, OK 73152
RI Type: Nonprofit college or university